Assessing how well ABBV-932 is absorbed in healthy adults
Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects
This study tests how well a new oral medication, ABBV-932, is absorbed in healthy adults and how food affects its absorption.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | AbbVie Industry-sponsored |
| Locations | 1 site (Grayslake, Illinois) |
| Trial ID | NCT06849791 on ClinicalTrials.gov |
What this trial studies
This study evaluates the relative bioavailability of ABBV-932, an oral medication, in healthy adult participants. It aims to understand how food affects the pharmacokinetics of this drug when taken orally. Participants will undergo assessments to ensure they meet health criteria, and their responses will be monitored throughout the study. The findings will help determine the optimal conditions for administering ABBV-932.
Who should consider this trial
Good fit: Ideal candidates are healthy adults with a BMI between 18.0 and 32.0 kg/m².
Not a fit: Patients with significant medical histories or conditions that could affect drug absorption will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the optimal administration of ABBV-932, potentially improving its effectiveness.
How similar studies have performed: Other studies assessing bioavailability of oral medications have shown success, indicating that this approach is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG Exclusion Criteria: * History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness. * History of any clinically significant sensitivity or allergy to any medication or food.
Where this trial is running
Grayslake, Illinois
- Acpru /Id# 266649 — Grayslake, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Abbvie Call Center
- Email: abbvieclinicaltrials@abbvie.com
- Phone: 844-663-3742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.